The study summarizes the evidence on fecal microbiota transplantation (FMT) as a treatment for inflammatory bowel disease (IBD). For umbrella review of systematic review and meta-analysis of observational studies and clinical trials until February 13, 2021, data sources such as PubMed, Scopus, Web of Science, EMBASE, and PROQUEST were searched. Previous systematic reviews and meta-analyses investigating the efficacy of FMT treatment of IBD, including ulcerative colitis (UC) and Crohn's disease (CD), were used as eligibility criteria. There were 17 reviews included; all of them were published within the last six years. The odds ratio (OR) of clinical remission after FMT in UC patients ranged from 2.29 to 3.67 compared to placebo; however, the OR for CD was unavailable in these studies. Clinical remission rates among FMT-treated CD patients were between 47.5 and 60.5 percent. While the current meta-analyses are inconclusive for the optimal route, dose, and frequency of FMT treatment in IBD patients, there is evidence for its efficacy in a subset of UC and CD patients. Long-term efficacy and interactions of FMT with other therapies should be studied in future studies.